Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06423911
Title Study of Olverembatinib (HQP1351) in Patients With CP-CML (POLARIS-2)
Acronym POLARIS-2
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Ascentage Pharma Group Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
MD Anderson Cancer Center RECRUITING Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field